Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Cell(2022)10.1016/j.cell.2021.12.046Source: DataRank Database

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses is a research paper published in Cell (2022). On theSindex it has a DataRank of 1.0. It has been cited 1,023 times.

N/A

1.0DataRank · unranked

Scored on demand from live citation data

Open Access1,023 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)Impact (FWCI 95.72)OA: hybridTopics (29)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

1.0

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (97)

Jiandong Huo ORCID,Daming Zhou ORCID,Jiří Zahradník ORCID,Piyada Supasa ORCID,Chang Liu ORCID

Live enrichment

PubMed:35081335 OpenAlex:https://openalex.org/W4206153788

Israel Science Foundation

Grant: 3814/19

National Institute for Health Research

Grant: 63/125,984

National Institute for Health Research

Grant: 277,546

National Institute for Health Research

Grant: PCT/GB2012/000467

MRC

Grant: MC_PC_19059

Fundação Oswaldo Cruz

Grant: VPPCB-007- FIO-18-2-30

Wellcome Trust

Grant: 203141/Z/16/Z

Wellcome Trust

Grant: 101122/Z/13/Z

Wellcome Trust

Grant: 090532/Z/09/Z

Bill & Melinda Gates Foundation

Grant: INV-016202

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Grant: 403276/2020-9

National Institutes of Health

Grant: U19 I082360

CAMS

Grant: 2018-I2M-2-002

Wellcome Trust

Grant: 203224/Z/16/Z

Medical Research Council

Grant: MR/S032304/1

Chief Scientist Office

Grant: COV/GLA/20/05

Medical Research Council

Grant: MC_PC_19025

Medical Research Council

Grant: MR/S020039/1

Medical Research Council

Grant: MR/V001329/1

Medical Research Council

Grant: MR/N00065X/1

Medical Research Council

Grant: MR/P011705/2

Medical Research Council

Grant: MC_UP_A090_1006

Medical Research Council

Grant: MR/P011705/1

FWCI

95.72

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.cell.com/cell/pdf/S0092-8674(21)01578-6.pdf

publisherhttps://www.cell.com/cell/pdf/S0092-8674(21)01578-6.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867421015786?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867421015786?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2021.12.046

Fields of Study

SARS-CoV-2 and COVID-19 ResearchBacillus and Francisella bacterial researchCOVID-19 Clinical Research Studies

Keywords

VirologyBiologyNeutralizationAntibodyNeutralizing antibodyTiterMonoclonal antibodyImmune escapeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)MutationPandemicImmune systemVirusGeneticsGeneInfectious disease (medical specialty)DiseaseOmicronRBDSARS-CoV-2Spikeimmune evasionreceptor interactionvaccinesvariants

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

10.6084/m9.figshare.19297886.v1figshare

Additional file 1 of Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

10.6084/m9.figshare.19297886figshare

Additional file 1 of A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

10.6084/m9.figshare.20267321.v1figshare

Additional file 1 of A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

10.6084/m9.figshare.20267321figshare

Additional file 1 of Mobility was a significant determinant of reported COVID-19 incidence during the Omicron Surge in the most populous U.S. Counties

10.6084/m9.figshare.20495971.v1figshare

Additional file 1 of Mobility was a significant determinant of reported COVID-19 incidence during the Omicron Surge in the most populous U.S. Counties

10.6084/m9.figshare.20495971figshare

Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

10.6084/m9.figshare.21085242.v1figshare

Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

10.6084/m9.figshare.21085242figshare

Additional file 1 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

10.6084/m9.figshare.23812506.v1figshare

Additional file 1 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

10.6084/m9.figshare.23812506figshare

Additional file 2 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

10.6084/m9.figshare.23812509.v1figshare

Additional file 2 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2